Neurelis
Drug Discovery · APIs & Drug Manufacturing
Jobs
$193k – $214k per year · In office · Full-Time · 5+ years exp · PhD · United States
Apply
Salary insights
Compensation ranges based on this company's open jobs
Median
$171k
Typical range
$81k – $214k
Open positions
4
3
Jobs
Junior
33.3%
Senior
66.7%
| Level | Jobs | Median | Typical range |
|---|---|---|---|
| Junior | 1 | $81k | $81k |
| Senior | 2 | $200k | $185k – $214k |
Highest paying role
Medical Science Liaison / Sr Medical Science Liaison | Northeast Region
$214k
Normalized to USD per year
Growth
Hiring Momentum
24/100
Hiring freeze
Open positions
5
0 opened / 0 closed in 30 days
Median time-to-fill
55 days
faster than 24% of the market
ATS activity
Every ~7 hours
Today
Hiring Dynamics
0%
Hiring Focus
The percentage next to each role is its share of the company's job openings over the last 90 days; the arrow shows the shift versus the previous period.
Marketing
29% ▲
Administrative
14% ▼
Analytics
14% ▼
Operations
14% ▲
Field & Service
14% ▼
Biotech
14% ▼
Financials
Total raised
$217.6M
Latest round
Venture - Series Unknown
Funding rounds
5
People
Craig Chambliss
Executive Officer, Director
George Stuart
Executive Officer
Kevin Li
Director
Priyanka Belawat
Director
Yong Zhang
Director
David Hale
Director
Cam Garner
Director
Huaizheng Peng
Director
Stephen Cartt
Director
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data
Tech stack
The technologies known for Neurelis, by layer.
Languages
SQL
Cloud & platforms
Power BI
Sign in to see how your skills match this stack
Sign In
Connections
List
Graph
Found in company registers, site code, DNS and hiring. Each connection shows how sure we are and the evidence, with its source and date.
Shared investors
HBM Healthcare InvestmentsVia a fund
OrbiMedVia a fund
196 portfolio companies: Cookiedatabase.org, ZYLOX-TONBRIDGE MEDICAL TECHNOLOGY CO., LTD., Z-Alpha Therapeutics and 193 more
Click a company to open it. Dashed lines are likely connections. The second step of the network is part of the Pro plan.
Owner
Same company
Same group
Likely
News
NEURELIS CEO CRAIG CHAMBLISS TO PRESENT KEYNOTE AT THE 14TH ANNUAL OUTSOURCING IN CLINICAL TRIALS SOUTHERN CALIFORNIA 2026 CONFERENCE
San Diego, CA - September 10, 2026 - Neurelis, Inc., the innovator behind VALTOCO (diazepam nasal spray), today announced its Founder and Chief Executive Officer Craig Chambliss will give a keynote address at the 14th Annual Outsourcing Clinical Trials (O
Read more
Report
Our Pipeline
Review the pipeline of products Neurelis has developed that enables patients with epilepsy or CNS disorders to gain greater control of their treatment journeys.
Read more
Report
Board of Directors
Discover the Neurelis Board of Directors, which possesses all the relevant experience needed to help a specialty pharmaceutical company thrive.
Read more
Report
NEURELIS CEO CRAIG CHAMBLISS NAMED EY US ENTREPRENEUR OF THE YEAR 2026 PACIFIC SOUTHWEST AWARD WINNER
Recognition honors business leaders for their ingenuity, courage, and entrepreneurial spirit San Diego, CA - June 15, 2026 - Neurelis, Inc., the innovator behind VALTOCO (diazepam nasal spray), today announced its Founder and Chief Executive Officer Craig
Read more
Report
NEURELIS HELPS SUPPORT NATIONAL NETWORK OF EPILEPSY AWARENESS AND SUPPORT AT FIRST EPILEPSY AWARENESS DAY AND EDUCATION EXPO AT WALT DISNEY WORLD
Company's Ambassadors to share their journeys with epilepsy and meaningfully connect with the epilepsy community in first east coast event San Diego, CA - April 23, 2026 - Neurelis, Inc., the innovator behind VALTOCO (diazepam nasal spray), today announce
Read more
Report
NEURELIS TO PRESENT ANALYSES OF IMMEDIATE-USE SEIZURE TREATMENT AT THE AMERICAN ACADEMY OF NEUROLOGY ANNUAL MEETING
Presentations to highlight analyses of both seizure termination and healthcare resource utilization as they relate to use of diazepam nasal spray San Diego, CA - April 16, 2026 - Neurelis, Inc., today announced details of two poster presentations at the A
Read more
Report
California Declaration
Neurelis Annual Declaration of Compliance based on a good faith understanding of the requirements of Section 119402 of the California Health & Safety Code.
Read more
Report
NEURELIS PROVIDES BUSINESS UPDATE HIGHLIGHTING TRANSFORMATIONAL 2025 RESULTS
2025 Net Revenue of $295-300M, EBITDA margin of 30%+ Expansion of VALTOCO (diazepam nasal spray) Patent Portfolio, Extending Market Exclusivity with multiple issuances through 2032 Accelerated Uptake with VALTOCO FDA Label Expansion Approval Including 2 t
Read more
Report
Neurelis Provides Business Update Highlighting Transformational 2025 Results
Neurelis, Inc., the innovator behind VALTOCO (diazepam nasal spray), today provides a business update highlighting the Company
Read more
Report
NEURELIS TO PRESENT CLINICAL DATA AT AMERICAN EPILEPSY SOCIETY ANNUAL MEETING
Collection of eight posters include analyses of data from studies of diazepam nasal spray in treatment of episodes of frequent seizures in people with epilepsy aged 2-65 years San Diego, CA - December 5, 2025 - Neurelis, Inc., the innovator behind VALTOCO
Read more
Report
Show more news
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
1
Countries
1
Busiest office
San Diego
San Diego
United States
HQ
myNEURELIS
3 open roles 4 posted in 90 days 33% engineering 200-500 est. staff $124k Avg Salary
hires for Analytics, Marketing, Operations
3430 Carmel Mountain Road, Suite 300, San Diego, CA 92121